Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | -0.40 | 0.36 | 0.00 |
| FCF Yield | -8.62% | -8.33% | -0.50% | -0.70% |
| EV / EBITDA | -14.69 | -51.20 | -67.90 | 39.50 |
| Quality | ||||
| ROIC | 397.97% | -16.80% | -9.54% | -0.92% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.07 | 0.67 | 0.30 | -0.28 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 7.13% | -284.93% | 28.53% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -1.57 | -14.34 | -4.23 | -0.06 |
| Interest Coverage | -21.04 | -14.78 | -12.37 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |